Comanche Biopharma Stock

www.comanchebiopharma.com/Healthcare / BioTech & PharmaFounded: 2020

Comanche Biopharma is a drug development company that uses pre-clinical biopharmaceutical research with the goal of lowering risks associated with pregnancy. With a mission to create accessible therapies that treat the root cause of preeclampsia, Comanche Biopharma designed molecules that decrease excess protein production, or sFlt1, as the biggest target of the disease. Comanche Biopharma was founded by Mike Young and Thomas Scott Johnson in 2020 and is headquartered in Concord, MA.

Register To Buy and Sell Shares

For more details on financing and valuation for Comanche Biopharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Comanche Biopharma’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Comanche Biopharma.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Thomas Johnson MD
Co-Founder & Chief Executive Officer
Michael Young
Co-Founder & President
Allison August
Chief Medical Officer

Board Members

Brendan Bulik-Sullivan Ph.D
GV
Clive Meanwell Ph.D
Population Health Partners
David Grayzel MD
Atlas Venture
Ketan Patel MD
F-Prime Capital
Muzammil Mansuri Ph.D
F-Prime Capital
Michael Young
Comanche Biopharma

Comanche Biopharma’s stock FAQs

plusminus

Can you buy Comanche Biopharma’s stock?

Comanche Biopharma is not publicly traded on NYSE or NASDAQ in the U.S. To buy Comanche Biopharma’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Comanche Biopharma’s stock?

Yes, you can sell stock of a private company like Comanche Biopharma. Forge can help you sell your Comanche Biopharma stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus

What is Comanche Biopharma’s stock price?

Comanche Biopharma is a privately held company and therefore does not have a public stock price. However, you may access Comanche Biopharma’s private market stock price with Forge Data.
plusminus

What is Comanche Biopharma’s stock ticker symbol?

Comanche Biopharma does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

Comanche Biopharma Corp. today announced the closing of an oversubscribed $75 million Series B financing to advance its mission to develop and make globally available the first treatment targeting a root cause of preeclampsia. Existing investors GV (Google Ventures), F-Prime Capital, Lilly Asia Ventures (LAV), and Longview Healthcare Ventures participated in the Series B round, joined by new investors New Enterprise Associates (NEA), who led the round, and Atlas Venture.
Updated on: Jun 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.